GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (STU:34LA) » Definitions » Market Cap

Alpine Immune Sciences (STU:34LA) Market Cap : €3,955.27 Mil (As of Apr. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Alpine Immune Sciences Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alpine Immune Sciences's share price for the quarter that ended in Dec. 2023 was €17.2. Alpine Immune Sciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 60.35 Mil. Therefore, Alpine Immune Sciences's market cap for the quarter that ended in Dec. 2023 was €1,037.98 Mil.

Alpine Immune Sciences's quarterly market cap increased from Jun. 2023 (€437.21 Mil) to Sep. 2023 (€492.74 Mil) and increased from Sep. 2023 (€492.74 Mil) to Dec. 2023 (€1,037.98 Mil).

Alpine Immune Sciences's annual market cap declined from Dec. 2021 (€332.14 Mil) to Dec. 2022 (€273.38 Mil) but then increased from Dec. 2022 (€273.38 Mil) to Dec. 2023 (€1,037.98 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alpine Immune Sciences's Enterprise Value for Today is €3,658.62 Mil.


Alpine Immune Sciences Market Cap Historical Data

The historical data trend for Alpine Immune Sciences's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Immune Sciences Market Cap Chart

Alpine Immune Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.88 234.46 332.14 273.38 1,037.98

Alpine Immune Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 273.38 325.23 437.21 492.74 1,037.98

Competitive Comparison of Alpine Immune Sciences's Market Cap

For the Biotechnology subindustry, Alpine Immune Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpine Immune Sciences's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's Market Cap distribution charts can be found below:

* The bar in red indicates where Alpine Immune Sciences's Market Cap falls into.



Alpine Immune Sciences Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Alpine Immune Sciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=€17.2*60.3475
=€1,037.98

Alpine Immune Sciences's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=€17.2*60.3475
=€1,037.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpine Immune Sciences  (STU:34LA) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Alpine Immune Sciences Market Cap Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpine Immune Sciences (STU:34LA) Business Description

Traded in Other Exchanges
Address
188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Alpine Immune Sciences (STU:34LA) Headlines

No Headlines